David B Shultz1, Leslie A Modlin1, Priya Jayachandran1, Rie Von Eyben1, Iris C Gibbs1, Clara Y H Choi2, Steven D Chang3, Griffith R Harsh3, Gordon Li3, John R Adler3, Steven L Hancock1, Scott G Soltys4. 1. Department of Radiation Oncology, Stanford University School of Medicine, Stanford, California. 2. Department of Radiation Oncology, Stanford University School of Medicine, Stanford, California; Department of Radiation Oncology, Santa Clara Valley Medical Center, San Jose, California. 3. Department of Neurosurgery, Stanford University School of Medicine, Stanford, California. 4. Department of Radiation Oncology, Stanford University School of Medicine, Stanford, California. Electronic address: sgsoltys@stanford.edu.
Abstract
PURPOSE: To report the outcomes of repeat stereotactic radiosurgery (SRS), deferring whole-brain radiation therapy (WBRT), for distant intracranial recurrences and identify factors associated with prolonged overall survival (OS). PATIENTS AND METHODS: We retrospectively identified 652 metastases in 95 patients treated with 2 or more courses of SRS for brain metastases, deferring WBRT. Cox regression analyzed factors predictive for OS. RESULTS: Patients had a median of 2 metastases (range, 1-14) treated per course, with a median of 2 courses (range, 2-14) of SRS per patient. With a median follow-up after first SRS of 15 months (range, 3-98 months), the median OS from the time of the first and second course of SRS was 18 (95% confidence interval [CI] 15-24) and 11 months (95% CI 6-17), respectively. On multivariate analysis, histology, graded prognostic assessment score, aggregate tumor volume (but not number of metastases), and performance status correlated with OS. The 1-year cumulative incidence, with death as a competing risk, of local failure was 5% (95% CI 4-8%). Eighteen (24%) of 75 deaths were from neurologic causes. Nineteen patients (20%) eventually received WBRT. Adverse radiation events developed in 2% of SRS sites. CONCLUSION: Multiple courses of SRS, deferring WBRT, for distant brain metastases after initial SRS, seem to be a safe and effective approach. The graded prognostic assessment score, updated at each course, and aggregate tumor volume may help select patients in whom the deferral of WBRT might be most beneficial.
PURPOSE: To report the outcomes of repeat stereotactic radiosurgery (SRS), deferring whole-brain radiation therapy (WBRT), for distant intracranial recurrences and identify factors associated with prolonged overall survival (OS). PATIENTS AND METHODS: We retrospectively identified 652 metastases in 95 patients treated with 2 or more courses of SRS for brain metastases, deferring WBRT. Cox regression analyzed factors predictive for OS. RESULTS:Patients had a median of 2 metastases (range, 1-14) treated per course, with a median of 2 courses (range, 2-14) of SRS per patient. With a median follow-up after first SRS of 15 months (range, 3-98 months), the median OS from the time of the first and second course of SRS was 18 (95% confidence interval [CI] 15-24) and 11 months (95% CI 6-17), respectively. On multivariate analysis, histology, graded prognostic assessment score, aggregate tumor volume (but not number of metastases), and performance status correlated with OS. The 1-year cumulative incidence, with death as a competing risk, of local failure was 5% (95% CI 4-8%). Eighteen (24%) of 75 deaths were from neurologic causes. Nineteen patients (20%) eventually received WBRT. Adverse radiation events developed in 2% of SRS sites. CONCLUSION: Multiple courses of SRS, deferring WBRT, for distant brain metastases after initial SRS, seem to be a safe and effective approach. The graded prognostic assessment score, updated at each course, and aggregate tumor volume may help select patients in whom the deferral of WBRT might be most beneficial.
Authors: Emory McTyre; Corbin A Helis; Michael Farris; Lisa Wilkins; Darrell Sloan; William H Hinson; J Daniel Bourland; William A Dezarn; Michael T Munley; Kounosuke Watabe; Fei Xing; Adrian W Laxton; Stephen B Tatter; Michael D Chan Journal: Neurosurgery Date: 2017-02-01 Impact factor: 4.654
Authors: Dylann Fujimoto; Rie von Eyben; Iris C Gibbs; Steven D Chang; Gordon Li; Griffith R Harsh; Steven Hancock; Nancy Fischbein; Scott G Soltys Journal: J Neurooncol Date: 2017-11-02 Impact factor: 4.130
Authors: Riccardo Soffietti; Ufuk Abacioglu; Brigitta Baumert; Stephanie E Combs; Sara Kinhult; Johan M Kros; Christine Marosi; Philippe Metellus; Alexander Radbruch; Salvador S Villa Freixa; Michael Brada; Carmine M Carapella; Matthias Preusser; Emilie Le Rhun; Roberta Rudà; Joerg C Tonn; Damien C Weber; Michael Weller Journal: Neuro Oncol Date: 2017-02-01 Impact factor: 12.300
Authors: John H Suh; Rupesh Kotecha; Samuel T Chao; Manmeet S Ahluwalia; Arjun Sahgal; Eric L Chang Journal: Nat Rev Clin Oncol Date: 2020-02-20 Impact factor: 66.675
Authors: Andrew T Roehrig; Ethan A Ferrel; Devon A Benincosa; Alexander R MacKay; Benjamin C Ling; Jonathan D Carlson; John J Demakas; Aaron Wagner; Wayne T Lamoreaux; Robert K Fairbanks; Jason A Call; Barton S Cooke; Ben Peressini; Christopher M Lee Journal: Surg Neurol Int Date: 2016-11-14